Nothing Special   »   [go: up one dir, main page]

BR112013027420A2 - "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos". - Google Patents

"uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".

Info

Publication number
BR112013027420A2
BR112013027420A2 BR112013027420A BR112013027420A BR112013027420A2 BR 112013027420 A2 BR112013027420 A2 BR 112013027420A2 BR 112013027420 A BR112013027420 A BR 112013027420A BR 112013027420 A BR112013027420 A BR 112013027420A BR 112013027420 A2 BR112013027420 A2 BR 112013027420A2
Authority
BR
Brazil
Prior art keywords
light chain
genetically modified
variable regions
antibody
mice
Prior art date
Application number
BR112013027420A
Other languages
English (en)
Inventor
Andrew J Murphy
David R Buckler
John Mcwhirter
Karolina A Hosiawa
Lynn Macdonald
Samuel Davis
Sean Stevens
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013027420(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112013027420A2 publication Critical patent/BR112013027420A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "animais não humanos que expressam anticorpos que possuem uma cadeia leve comum". a presente invenção refere-se a um camundongo geneticamente modificado, em que o camundongo expressa um repertório de cadeia leve de imunoglobulina caracterizado por um número limitado de domínios variáveis de cadeia leve. são fornecidos camundongos que expressam apenas um ou alguns domínios de cadeia variável leve de imunoglobulina de um repertório limitado em sua linhagem germinativa. métodos para fazer regiões variáveis de cadeia leve em camundongos, incluindo regiões variáveis de cadeia leve humana são fornecidos. métodos para fazer regiões variáveis humanas adequadas para uso em proteínas de ligação multiespecíficas, por exemplo, anticorpos biespecíficos, são fornecidos.
BR112013027420A 2011-04-25 2012-04-24 "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos". BR112013027420A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/093,156 US20120021409A1 (en) 2010-02-08 2011-04-25 Common Light Chain Mouse
PCT/US2012/034737 WO2012148873A2 (en) 2011-04-25 2012-04-24 Non-human animals expressing antibodies having a common light chain

Publications (1)

Publication Number Publication Date
BR112013027420A2 true BR112013027420A2 (pt) 2016-08-09

Family

ID=46000410

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027420A BR112013027420A2 (pt) 2011-04-25 2012-04-24 "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".

Country Status (25)

Country Link
US (2) US20120021409A1 (pt)
EP (2) EP2989893B1 (pt)
JP (2) JP6393613B2 (pt)
KR (1) KR101995753B1 (pt)
CN (2) CN103596424B (pt)
AU (3) AU2012249953B2 (pt)
BR (1) BR112013027420A2 (pt)
CA (1) CA2846806A1 (pt)
CY (2) CY1117606T1 (pt)
DK (2) DK2989893T3 (pt)
ES (2) ES2573828T5 (pt)
HK (2) HK1220866A1 (pt)
HR (2) HRP20160484T4 (pt)
HU (2) HUE027949T2 (pt)
IL (1) IL228929A0 (pt)
LT (1) LT2989893T (pt)
MX (1) MX353609B (pt)
PL (2) PL2989893T3 (pt)
PT (1) PT2989893T (pt)
RS (2) RS59331B1 (pt)
RU (2) RU2017108634A (pt)
SG (1) SG194466A1 (pt)
SI (2) SI2989893T1 (pt)
SM (1) SMT201600133B (pt)
WO (1) WO2012148873A2 (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2792236B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR101995735B1 (ko) 2010-02-08 2019-07-03 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
CA2819530C (en) 2010-11-30 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
SI4067496T1 (sl) 2011-02-25 2023-07-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
RU2013141078A (ru) 2011-02-28 2015-04-10 Ф. Хоффманн-Ля Рош Аг Одновалентные антигенсвязывающие белки
PL2739740T3 (pl) 2011-08-05 2020-06-01 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
IL292030B2 (en) 2011-10-17 2023-07-01 Regeneron Pharma Mice with restricted immunoglobulin heavy chain
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201913164YA (en) 2011-12-20 2020-03-30 Regeneron Pharma Humanized light chain mice
RU2644684C2 (ru) 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
RU2664473C2 (ru) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
PL3597037T3 (pl) * 2012-06-12 2021-10-25 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
SI2840892T1 (en) * 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
RU2015143108A (ru) * 2013-03-13 2017-04-20 Регенерон Фарматютикалз, Инк. Мышь с общей легкой цепью
CA2903698C (en) * 2013-03-13 2023-02-28 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
BR112016005912A2 (pt) 2013-09-18 2017-09-26 Regeneron Pharma sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico
JP7133902B2 (ja) * 2013-10-01 2022-09-09 カイマブ・リミテッド 動物モデル及び治療用分子
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
JP6636498B2 (ja) * 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
ME03806B (me) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
ES2881346T3 (es) 2014-12-19 2021-11-29 Regenesance B V Anticuerpos que se unen a C6 humano y usos de los mismos
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
US11033009B2 (en) * 2015-08-27 2021-06-15 Crystal Bioscience Inc. Transgenic chicken for production of antibodies having a common light chain
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017123804A1 (en) 2016-01-13 2017-07-20 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
SI3462853T1 (sl) * 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CU20210030A7 (es) 2016-10-13 2021-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
KR20200135830A (ko) 2018-03-23 2020-12-03 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
JP7182647B2 (ja) 2018-06-14 2022-12-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
CA3150168A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
AU2020395122A1 (en) 2019-12-02 2022-06-09 Regeneron Pharmaceuticals, Inc. Peptide-MHC II protein constructs and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
JP2024501796A (ja) 2020-12-23 2024-01-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 膜貫通タンパク質に結合する抗体、および抗体を産生する細胞を取得する方法
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US20240263190A1 (en) * 2023-01-18 2024-08-08 Gilead Sciences, Inc. Human immunoglobulin binary light chain transgene constructs and uses thereof
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998050431A2 (en) * 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
EP1298207B2 (de) * 2001-10-01 2015-12-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
EP2319301B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
WO2003061363A2 (en) * 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
CN101824090B (zh) * 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
EP1966241A2 (en) * 2005-12-05 2008-09-10 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
RS52643B (en) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AU2008224950B2 (en) * 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
KR102261586B1 (ko) * 2008-06-27 2021-06-08 메뤼스 엔.페. 항체 생산 비-인간 포유동물
US9403904B2 (en) * 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
JP5804521B2 (ja) * 2009-05-29 2015-11-04 モルフォシス・アー・ゲー コレクション及びその使用方法
KR20120027055A (ko) * 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
KR101995735B1 (ko) * 2010-02-08 2019-07-03 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
CN104582476B (zh) 2012-06-05 2017-03-08 瑞泽恩制药公司 使用共同轻链制备完全人双特异性抗体的方法

Also Published As

Publication number Publication date
US20150313193A1 (en) 2015-11-05
CN103596424A (zh) 2014-02-19
IL228929A0 (en) 2013-12-31
CY1122036T1 (el) 2020-10-14
CY1117606T1 (el) 2017-04-26
PL2701499T3 (pl) 2017-03-31
RS59331B1 (sr) 2019-10-31
SI2701499T2 (sl) 2022-01-31
PL2989893T3 (pl) 2019-12-31
CN105884887A (zh) 2016-08-24
WO2012148873A3 (en) 2013-02-07
ES2573828T5 (es) 2022-02-28
AU2018236913A1 (en) 2018-10-25
DK2701499T4 (da) 2021-11-15
AU2012249953A1 (en) 2013-05-02
EP2701499B1 (en) 2016-02-10
RU2017108634A (ru) 2019-01-22
MX353609B (es) 2018-01-18
WO2012148873A2 (en) 2012-11-01
SI2701499T1 (sl) 2016-10-28
KR20140024909A (ko) 2014-03-03
RS54831B2 (sr) 2021-12-31
JP2016178948A (ja) 2016-10-13
LT2989893T (lt) 2019-09-10
US20120021409A1 (en) 2012-01-26
RU2013152221A (ru) 2015-05-27
DK2989893T3 (da) 2019-09-09
ES2573828T3 (es) 2016-06-10
EP2989893B1 (en) 2019-06-19
DK2701499T3 (en) 2016-05-23
SMT201600133B (it) 2016-07-01
HUE045401T2 (hu) 2019-12-30
KR101995753B1 (ko) 2019-07-03
HK1193718A1 (zh) 2014-10-03
EP2701499B2 (en) 2021-08-18
AU2012249953B2 (en) 2016-01-28
HUE027949T2 (en) 2016-11-28
AU2016202609A1 (en) 2016-05-19
HRP20191680T1 (hr) 2019-12-13
NZ617158A (en) 2016-04-29
EP2701499B9 (en) 2016-05-18
AU2016202609B2 (en) 2018-07-12
RS54831B1 (sr) 2016-10-31
HRP20160484T4 (hr) 2021-12-10
JP6522557B2 (ja) 2019-05-29
WO2012148873A4 (en) 2013-03-14
RU2614859C2 (ru) 2017-03-29
MX2013012500A (es) 2014-02-03
HK1220866A1 (zh) 2017-05-19
ES2743681T3 (es) 2020-02-20
CN103596424B (zh) 2016-01-20
SI2989893T1 (sl) 2019-10-30
EP2701499A2 (en) 2014-03-05
SG194466A1 (en) 2013-12-30
JP6393613B2 (ja) 2018-09-19
PT2989893T (pt) 2019-09-23
CA2846806A1 (en) 2012-11-01
JP2014516518A (ja) 2014-07-17
HRP20160484T1 (hr) 2016-06-03
EP2989893A1 (en) 2016-03-02
EP2701499B8 (en) 2016-03-16
AU2016202609A2 (en) 2017-02-02
PL2701499T5 (pl) 2021-12-13

Similar Documents

Publication Publication Date Title
BR112013027420A2 (pt) "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".
MX353278B (es) Raton con cadena ligera comun.
MX2015012540A (es) Ratón de cadena ligera común.
CR20150095A (es) Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica
AR093984A1 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EA201792657A1 (ru) Связывающие lag-3 молекулы и способы их применения
GT201400045A (es) Anticuerpo anti-abtcr
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
GT201300149A (es) Proteinas de union al tnf-a
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CO7250445A2 (es) Proteínas de unión a antígeno st2
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
MX2014011051A (es) Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PA8830701A1 (es) Anticuerpos contra il-6 y sus usos
MY191512A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]